Press "Enter" to skip to content

Antidepressant Reduces the Risk of Hospitalization

In research looking for current medications that could be repurposed to treat coronavirus, an inexpensive Antidepressant reduced the requirement for hospitalisation among high-risk patients with COVID-19.

The medication, which is used to treat depression and obsessive-compulsive disorder, was put to the test since it was known to lower inflammation and had shown promise in smaller studies. They have shared their findings with the National Institutes of Health in the United States, which produces treatment guidelines, and they’re hoping for a recommendation from the World Health Organization.

Antidepressant Reduces the Risk of HospitalizationDr Edward Mills of McMaster University in Hamilton, Ontario and the co-author of the study said that if the world health organisation recommends this, you will see it extensively adopted research adding that the medicine is readily available in many poor countries. The pill, called fluvoxamine, would cost $4 for a course of COVID-19 treatment. By comparison, antibody IV treatments cost about $2,000 and Merck’s experimental antiviral pill for COVID-19 is about $700 per course. Some experts predict various treatments will be used in combination to fight the coronavirus.

In the group that took the drug, 11% needed hospitalization or an extended ER stay, compared to 16% of those on dummy pills.The results, published Wednesday in the journal Lancet Global Health, were so strong that independent experts monitoring the study recommended stopping it early because the results were clear.

Be First to Comment

Leave a Reply

Your email address will not be published. Required fields are marked *